Stargardt Disease clinical trials at UCSF

2 in progress, 1 open to eligible people

Stargardt disease is an inherited eye disorder that can cause vision decline. UCSF is conducting a trial to study the effects of an experimental drug on those with Stargardt's gene. This research will gather data on the drug's safety and processing in the body.

Showing trials for

  • ACDN-01 in ABCA4-related Stargardt Retinopathy (STELLAR)

    open to eligible people ages 18 years and up

    This study is an open-label, single ascending dose clinical trial in participants who have ABCA4-related retinopathies. This is the first-in-human clinical trial in which ACDN-01 will be evaluated for safety, tolerability, and preliminary efficacy following a single subretinal injection of ACDN-01.

    San Francisco, California and other locations

  • Tinlarebant in Subjects With Stargardt Disease

    Sorry, not currently recruiting here

    The goal of this clinical trial is to evaluate the safety, tolerability, and efficacy of tinlarebant in subjects with Stargardt Disease

    San Francisco, California and other locations

Our lead scientists for Stargardt Disease research studies include .

Last updated: